Celltrion sees 12% YoY growth in biosimilars business in 2023, driven by new portfolios like Remsima SC and Yuflyma. The company targets over 60% global sales growth, with 40%+ EBITDA margin in 2024.
Boomeranged on Thu, 18 Apr 2024 14:07
Celltrion will cancel 1.1M shares (~10% of holdings) for ~KRW200B. Parallelly, the company announced buyback of 436K shares for ~KRW75B, matching the amount spent in March buyback. In January, the company retired 20.6% of its holding for KRW400B. Celltrion’s new biosimilar Zymfentra has been listed by one of the top three PBMs in US, which should propel its adoption among the insured patients.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.